CHUGAI PHARMA, Jan-Sep (Cumulative 3Q) Net Income Increases by 3%

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Fri Oct 24, 2025 5:00 pm JST Earnings

4519 CHUGAI PHARMACEUTICAL CO., LTD. 【IFRS】

Earnings Report

CHUGAI PHARMACEUTICAL CO., LTD. <4519> [TSE Prime] announced its financial results (based on IFRS) after the market closed on October 24th (17:00). The consolidated net income for the cumulative third quarter of the fiscal year ending December 2025 (January to September) increased 3.3% from the same period last year, reaching 305 billion yen.

In the most recent three-month period, from July to September (3Q), the consolidated net income amounted to 111 billion yen, an increase of 1.6% compared to the same period last year. However, the operating profit margin decreased from 50.8% in the same period last year to 47.0%.

Kabutan News

Actual Results

Accumulated Results 3rd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Jan - Sep, 2023	837,555	317,598	321,131	234,266	142.4	72.4	Oct 24, 2023	IFRS
Jan - Sep, 2024	868,538	418,602	417,527	295,758	179.8	76.9	Oct 25, 2024	IFRS
Jan - Sep, 2025	911,640	429,827	427,902	305,602	185.7	ー	Oct 24, 2025	IFRS
YoY	+5.0%	+2.7%	+2.5%	+3.3%	+3.3%

Current Period Guidance

Second Half Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Jul - Dec, 2024	617,751	283,807	284,344	201,055	122.2	57	Jan 30, 2025	IFRS
Jul - Dec, 2025 Guidance	611,537	ー	ー	ー	－	125	Jul 24, 2025	IFRS
YoY	-1.0%	－	－	－	－

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec, 2023	1,111,367	439,174	443,821	325,472	197.8	80	Feb 1, 2024	IFRS
Dec, 2024	1,170,611	542,002	543,034	387,317	235.4	98	Jan 30, 2025	IFRS
Dec, 2025 Guidance	1,190,000	ー	ー	ー	－	250	Jan 30, 2025	IFRS
YoY	+1.7%	－	－	－	－

Quarterly Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Jul - Sep, 2024	315,678	160,407	158,837	109,496	66.6	50.8	Oct 25, 2024	IFRS
Oct - Dec, 2024	302,073	123,400	125,507	91,559	55.6	40.9	Jan 30, 2025	IFRS
Jan - Mar, 2025	288,459	136,651	135,829	97,234	59.1	47.4	Apr 24, 2025	IFRS
Apr - Jun, 2025	290,004	136,691	136,001	97,155	59.0	47.1	Jul 24, 2025	IFRS
Jul - Sep, 2025	333,177	156,485	156,072	111,213	67.6	47.0	Oct 24, 2025	IFRS
YoY	+5.5%	-2.4%	-1.7%	+1.6%	+1.5%